查看购物车
  • Traditional Chinese
  • English
  • Japanese
2021-2031 年北美基因检测服务市场报告（范围、细分、动态和竞争分析）
市场调查报告书
商品编码
1819710

2021-2031 年北美基因检测服务市场报告（范围、细分、动态和竞争分析）

North America Genetic Testing Services Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 176 Pages | 订单完成后即时交付

价格

北美基因检测服务市场预计将实现显着成长，预计到 2031 年将达到约 58.9293 亿美元，高于 2023 年的 18.0802 亿美元。这一成长轨迹表明，2023 年至 2031 年的年复合成长率(CAGR) 为 15.9%。

执行摘要和市场分析

北美基因检测服务产业正在经历大幅扩张，这主要得益于技术进步、个人化医疗需求的不断增长以及对预防性医疗保健的日益重视。美国是该市场的主要参与者，其特点是基因检测广泛应用于各种领域，包括癌症诊断、产前筛检和遗传性疾病的鑑定。 23andMe、Illumina 和 LabCorp 等知名公司的加入，透过不断创新和改进检测技术，进一步推动了市场的成长。此外，政府支持基因组学研究的措施和医疗保健资金的增加预计将显着促进市场成长，巩固北美作为全球基因检测服务领导者的地位。

市场区隔分析

基因检测服务市场可以根据服务类型、疾病和服务提供者进行细分。

  • 服务类型：市场分为几类，包括预测性检测、带因者检测、产前检测、新生儿筛检、诊断性基因检测等。 2023年，预测性检测领域成为市场的最大贡献者。
  • 疾病：市场也依疾病细分，包括癌症、心血管疾病、代谢失调和其他疾病。癌症领域在2023年占据了最大的市场份额，反映了基因检测在癌症风险评估和管理中的重要作用。
  • 服务提供者：市场分为医院实验室、诊断实验室和其他服务提供者。 2023年，医院实验室占据了最大的份额，凸显了其在提供基因检测服务方面的关键作用。

市场展望

全球遗传疾病的日益普及是推动基因检测服务需求成长的主要因素。遗传性疾病通常表现为罕见且非典型的症状，其中许多目前无法治癒。根据世界卫生组织 (WHO) 2021 年的数据，每 1,000 人中约有 10 人患有单基因疾病，全球约有 7,000 万至 8,000 万人患有单基因疾病。全球基因组织报告称，已发现约 7,000 种罕见疾病和病症，且新疾病仍在持续发现中。

谢菲尔德大学的研究表明，全球约有3亿人患有遗传疾病。例如，MJH Life Sciences 2022年的报告估计，每年约有30万名新生儿被诊断​​出患有镰状细胞疾病，约占全球人口的5%。此外，2023年8月发表的一项研究强调，每500名非裔美国人中就有1人患有镰状细胞疾病，约12分之一的非裔美国人携带这种常染色体隐性突变。

遗传疾病发生率的上升是基因检测服务市场成长的主要驱动力。

国家洞察

北美基因检测服务市场包括美国、加拿大和墨西哥，其中美国在 2023 年占据最大市场份额。根据美国疾病管制与预防中心 (CDC) 的数据，2020 年美国诊断出约 1,603,844 例新癌症病例，导致 602,347 例癌症死亡。预计 2023 年美国将新增约 1,958,310 例癌症病例，死亡人数为 609,820 人。国际癌症研究机构预计，到 2040 年，美国新发癌症发生率可能达到 3,020 万人。许多癌症都具有遗传成分，因此基因检测对于评估有癌症家族史的个体的风险因素至关重要。

美国政府问责局2021年10月报告称，美国有2500万至3000万人患有罕见疾病，其中近一半患者是儿童。据估计，80%的罕见疾病源自于遗传。

在过去的几十年里，基因检测已成为美国医疗保健体係不可或缺的一部分。随着基因检测的普及，确保全国检测品质的需求也日益增长。 《临床实验室改进修正案》（CLIA）对基因检测实验室进行监管，确保其符合品质控制和保证标准。此外，美国食品药物管理局（FDA）也负责监督临床实验室使用的基因检测试剂盒的品质。

受癌症、自体免疫疾病和传染病等领域应用的推动，美国对基因检测的需求预计将持续成长。基因检测产品的创新，例如阿韦利诺实验室的AvaGen眼科基因检测以及美国食品药物管理局(FDA)批准的脆性X综合征基因检测，都显示了该领域的持续进步。

公司简介

北美基因检测服务市场的主要参与者包括 Eurofins Scientific SE、Exact Sciences Corp、Laboratory Corp of America Holdings、23andMe Holding Co、Ambry Genetics Corp、Quest Diagnostics Inc、Illumina Inc、F. Hoffmann-La Roche Ltd、NeoGenomics Inc、Cento NV Inc、VERITAS INTERCONTINENTAL 和 GeneDx, LLC。这些公司正在采用各种策略，包括扩张、产品创新和併购，以增强其市场影响力并为消费者提供创新解决方案。

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：北美基因检测服务市场格局

  • PEST分析

第五章：北美基因检测服务市场－关键市场动态

  • 市场驱动因素
    • 遗传疾病盛行率上升
    • 提高对个人化医疗的认识和接受度
    • 直接面向消费者（DTC）基因检测的偏好日益增长
  • 市场限制
    • 基因检测的社会和伦理影响
    • 基因服务的可负担性
  • 市场机会
    • 发展中国家尚未开发的新兴市场
  • 未来趋势
    • 人工智慧基因检测
  • 影响分析：

第六章：基因检测服务市场－北美分析

  • 2021-2031年北美基因检测服务市场收入
  • 北美基因检测服务市场预测分析

第七章：北美基因检测服务市场分析－依服务类型

  • 预测测试
  • 携带者检测
  • 产前检查
  • 新生儿筛检
  • 诊断性基因检测
  • 其他的

第八章：北美基因检测服务市场分析－按疾病

  • 癌症
  • 心血管疾病
  • 代谢性疾病
  • 其他疾病

第九章：北美基因检测服务市场分析－服务供应商

  • 医院实验室
  • 诊断实验室
  • 其他服务提供者

第 10 章：北美基因检测服务市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 11 章：基因检测服务市场-产业格局

  • 概述
  • 基因检测服务市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十二章：公司简介

  • Eurofins Scientific SE
  • Exact Sciences Corp
  • Laboratory Corp of America Holdings
  • 23andMe Holding Co
  • Ambry Genetics Corp
  • Quest Diagnostics Inc
  • Illumina Inc
  • F. Hoffmann-La Roche Ltd
  • NeoGenomics Inc
  • Centogene NV
  • Ancestry Genomics Inc
  • Gene By Gene Ltd
  • SIVOTEC BioInformatics LLC
  • Progenesis
  • Fulgent Genetics, Inc
  • VERITAS INTERCONTINENTAL
  • GeneDx, LLC

第 13 章：附录

Product Code: TIPRE00009262

The North American genetic testing services market is poised for remarkable growth, projected to reach approximately USD 5,892.93 million by 2031, up from USD 1,808.02 million in 2023. This growth trajectory indicates a compound annual growth rate (CAGR) of 15.9% from 2023 to 2031.

Executive Summary and Market Analysis

The genetic testing services sector in North America is witnessing substantial expansion, primarily fueled by advancements in technology, a rising demand for personalized medicine, and an increasing emphasis on preventive healthcare. The United States stands out as a major player in this market, characterized by the widespread use of genetic testing for various applications, including cancer diagnosis, prenatal screening, and the identification of hereditary diseases. The presence of prominent companies such as 23andMe, Illumina, and LabCorp is further propelling market growth through continuous innovation and enhancements in testing technologies. Additionally, government initiatives supporting genomics research and increased healthcare funding are expected to significantly contribute to the market's growth, solidifying North America's position as a global leader in genetic testing services.

Market Segmentation Analysis

The genetic testing services market can be segmented based on service type, disease, and service provider.

  • Service Type: The market is divided into several categories, including predictive testing, carrier testing, prenatal testing, newborn screening, diagnostic genetic testing, and others. In 2023, the predictive testing segment emerged as the largest contributor to the market.
  • Disease: The market is also segmented by disease, including cancer, cardiovascular diseases, metabolic disorders, and other conditions. The cancer segment held the largest market share in 2023, reflecting the significant role of genetic testing in cancer risk assessment and management.
  • Service Provider: The market is categorized into hospital-based laboratories, diagnostic laboratories, and other service providers. Hospital-based laboratories accounted for the largest share in 2023, highlighting their critical role in delivering genetic testing services.

Market Outlook

The increasing prevalence of genetic diseases globally is a major factor driving the demand for genetic testing services. Genetic disorders often present with rare and atypical symptoms, many of which are currently incurable. According to the World Health Organization (WHO) in 2021, approximately 10 out of every 1,000 individuals are affected by single-gene diseases, translating to an estimated 70 to 80 million people worldwide. The Global Genes organization reports that around 7,000 rare diseases and disorders have been identified, with new conditions being discovered regularly.

Research from the University of Sheffield indicates that approximately 300 million people globally are living with genetic diseases. For instance, a 2022 report by MJH Life Sciences estimated that around 300,000 newborns are diagnosed with sickle cell disease each year, representing about 5% of the global population. Furthermore, a study published in August 2023 highlighted that 1 in 500 African Americans is affected by sickle cell disease, with about 1 in 12 carrying the autosomal recessive mutation.

This rising incidence of genetic diseases is a key driver for the growth of the genetic testing services market.

Country Insights

The North American genetic testing services market includes the United States, Canada, and Mexico, with the US holding the largest market share in 2023. According to the Centers for Disease Control and Prevention (CDC), approximately 1,603,844 new cancer cases were diagnosed in the US in 2020, resulting in 602,347 cancer-related deaths. Projections for 2023 estimate around 1,958,310 new cancer cases and 609,820 deaths. The International Agency for Research on Cancer anticipates that new cancer incidences could reach 30.2 million by 2040. Many cancers have a hereditary component, making genetic testing essential for assessing risk factors in individuals with a family history of cancer.

The US Government Accountability Office reported in October 2021 that between 25 to 30 million Americans suffer from rare diseases, with nearly half of these patients being children. It is estimated that 80% of rare diseases are genetic in origin.

Genetic testing has become integral to the US healthcare system over the past few decades. As the adoption of genetic testing increases, there is a growing need to ensure the quality of tests conducted across the country. The Clinical Laboratory Improvement Amendments (CLIA) regulate genetic testing laboratories, ensuring compliance with quality control and assurance standards. Additionally, the US Food and Drug Administration (FDA) oversees the quality of genetic testing kits used by clinical laboratories.

The demand for genetic testing in the US is expected to continue growing, driven by its applications in cancer, autoimmune diseases, and infectious diseases. Innovations in genetic testing products, such as Avellino Labs' AvaGen genetic eye test and the FDA's approval of a genetic test for Fragile X Syndrome, illustrate the ongoing advancements in this field.

Company Profiles

Key players in the North American genetic testing services market include Eurofins Scientific SE, Exact Sciences Corp, Laboratory Corp of America Holdings, 23andMe Holding Co, Ambry Genetics Corp, Quest Diagnostics Inc, Illumina Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Inc, Centogene NV, Ancestry Genomics Inc, Gene By Gene Ltd, SIVOTEC BioInformatics LLC, Progenesis, Fulgent Genetics, Inc, VERITAS INTERCONTINENTAL, and GeneDx, LLC. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. North America Genetic Testing Services Market Landscape

  • 4.1 PEST Analysis

5. North America Genetic Testing Services Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Genetic Diseases
    • 5.1.2 Increasing Awareness and Acceptance of Personalized Medicines
    • 5.1.3 Growing Preference for Direct-To-Consumer (DTC) Genetic Testing
  • 5.2 Market Restraints
    • 5.2.1 Social and Ethical Implications of Genetic Testing
    • 5.2.2 Affordability of Genetic Services
  • 5.3 Market Opportunities
    • 5.3.1 Untapped Emerging Markets in Developing Countries
  • 5.4 Future Trends
    • 5.4.1 Artificial Intelligence-Powered Genetic Testing
  • 5.5 Impact Analysis:

6. Genetic Testing Services Market - North America Analysis

  • 6.1 North America Genetic Testing Services Market Revenue (US$ Million), 2021-2031
  • 6.2 North America Genetic Testing Services Market Forecast Analysis

7. North America Genetic Testing Services Market Analysis - by Service Type

  • 7.1 Predictive Testing
    • 7.1.1 Overview
    • 7.1.2 Predictive Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Carrier Testing
    • 7.2.1 Overview
    • 7.2.2 Carrier Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Prenatal Testing
    • 7.3.1 Overview
    • 7.3.2 Prenatal Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 New-born Screening
    • 7.4.1 Overview
    • 7.4.2 New-born Screening: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Diagnostic Genetic Testing
    • 7.5.1 Overview
    • 7.5.2 Diagnostic Genetic Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Genetic Testing Services Market Analysis - by Disease

  • 8.1 Cancer
    • 8.1.1 Overview
    • 8.1.2 Cancer: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Cardiovascular Diseases
    • 8.2.1 Overview
    • 8.2.2 Cardiovascular Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Metabolic Diseases
    • 8.3.1 Overview
    • 8.3.2 Metabolic Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Other Diseases
    • 8.4.1 Overview
    • 8.4.2 Other Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Genetic Testing Services Market Analysis - by Service Providers

  • 9.1 Hospital-Based Laboratories
    • 9.1.1 Overview
    • 9.1.2 Hospital-Based Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Overview
    • 9.2.2 Diagnostic Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Other Service Providers
    • 9.3.1 Overview
    • 9.3.2 Other Service Providers: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Genetic Testing Services Market - Country Analysis

  • 10.1 North America
    • 10.1.1 North America Genetic Testing Services Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 North America Genetic Testing Services Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 United States: North America Genetic Testing Services Market Share - by Service Type
        • 10.1.1.2.2 United States: North America Genetic Testing Services Market Share - by Disease
        • 10.1.1.2.3 United States: North America Genetic Testing Services Market Share - by Cancer Disease
        • 10.1.1.2.4 United States: North America Genetic Testing Services Market Share - by Service Providers
      • 10.1.1.3 Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 Canada: North America Genetic Testing Services Market Share - by Service Type
        • 10.1.1.3.2 Canada: North America Genetic Testing Services Market Share - by Disease
        • 10.1.1.3.3 Canada: North America Genetic Testing Services Market Share - by Cancer Disease
        • 10.1.1.3.4 Canada: North America Genetic Testing Services Market Share - by Service Providers
      • 10.1.1.4 Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 Mexico: North America Genetic Testing Services Market Share - by Service Type
        • 10.1.1.4.2 Mexico: North America Genetic Testing Services Market Share - by Disease
        • 10.1.1.4.3 Mexico: North America Genetic Testing Services Market Share - by Cancer Disease
        • 10.1.1.4.4 Mexico: North America Genetic Testing Services Market Share - by Service Providers

11. Genetic Testing Services Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Genetic Testing Services Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Eurofins Scientific SE
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Exact Sciences Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Laboratory Corp of America Holdings
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 23andMe Holding Co
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Ambry Genetics Corp
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Quest Diagnostics Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Illumina Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 F. Hoffmann-La Roche Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 NeoGenomics Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Centogene NV
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Ancestry Genomics Inc
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments
  • 12.12 Gene By Gene Ltd
    • 12.12.1 Key Facts
    • 12.12.2 Business Description
    • 12.12.3 Products and Services
    • 12.12.4 Financial Overview
    • 12.12.5 SWOT Analysis
    • 12.12.6 Key Developments
  • 12.13 SIVOTEC BioInformatics LLC
    • 12.13.1 Key Facts
    • 12.13.2 Business Description
    • 12.13.3 Products and Services
    • 12.13.4 Financial Overview
    • 12.13.5 SWOT Analysis
    • 12.13.6 Key Developments
  • 12.14 Progenesis
    • 12.14.1 Key Facts
    • 12.14.2 Business Description
    • 12.14.3 Products and Services
    • 12.14.4 Financial Overview
    • 12.14.5 SWOT Analysis
    • 12.14.6 Key Developments
  • 12.15 Fulgent Genetics, Inc
    • 12.15.1 Key Facts
    • 12.15.2 Business Description
    • 12.15.3 Products and Services
    • 12.15.4 Financial Overview
    • 12.15.5 SWOT Analysis
    • 12.15.6 Key Developments
  • 12.16 VERITAS INTERCONTINENTAL
    • 12.16.1 Business Description
    • 12.16.2 Products and Services
    • 12.16.3 Financial Overview
    • 12.16.4 SWOT Analysis
    • 12.16.5 Key Developments
  • 12.17 GeneDx, LLC
    • 12.17.1 Key Facts
    • 12.17.2 Business Description
    • 12.17.3 Products and Services
    • 12.17.4 Financial Overview
    • 12.17.5 SWOT Analysis
    • 12.17.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Genetic Testing Services Market Segmentation
  • Table 2. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Service Type
  • Table 4. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Disease
  • Table 5. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Service Providers
  • Table 6. North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 7. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
  • Table 8. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease
  • Table 9. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cancer Disease
  • Table 10. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Providers
  • Table 11. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
  • Table 12. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease
  • Table 13. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cancer Disease
  • Table 14. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Providers
  • Table 15. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
  • Table 16. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease
  • Table 17. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Cancer Disease
  • Table 18. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Providers
  • Table 19. Recent Organic Growth Strategies in Genetic Testing Services Market
  • Table 20. Recent Inorganic Growth Strategies in the Genetic Testing Services Market
  • Table 21. Glossary of Terms, Genetic Testing Services Market

List Of Figures

  • Figure 1. North America Genetic Testing Services Market Segmentation - Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Genetic Testing Services Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Genetic Testing Services Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Genetic Testing Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 7. Predictive Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. carrier testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Prenatal Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. New-born Screening: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Diagnostic Genetic Testing: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Others: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. North America Genetic Testing Services Market Share (%) - by Disease (2023 and 2031)
  • Figure 14. Cancer: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Cardiovascular Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Metabolic Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. Other Diseases: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. North America Genetic Testing Services Market Share (%) - by Service Providers (2023 and 2031)
  • Figure 19. Hospital-Based Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Diagnostic Laboratories: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Other Service Providers: North America Genetic Testing Services Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. North America Genetic Testing Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. United States: North America Genetic Testing Services Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. Canada: North America Genetic Testing Services Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Mexico: North America Genetic Testing Services Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. Growth Strategies in Genetic Testing Services Market